Below are some of the key findings from this testicular cancer drugs market analysis report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Global testicular cancer drugs industry overview
The availability of combination therapies for the treatment of testicular cancer is one of the critical reasons that will drive the testicular cancer drugs market’s growth. Combination therapy is preferred over single-drug therapy as its use has increased the survival rate to 95% in patients with testicular cancer. This therapy consists of two treatment regimens, namely etoposide, ifosfamide, and cisplatin combination therapy and bleomycin, etoposide, and cisplatin therapy. This has encouraged researchers from various institutes such as the Institute of Cancer Research to discover new combination therapies that can treat drug-resistant testicular germ cell cancer.
The development of novel treatment therapies by researchers has also encouraged the production of combinations of existing approved testicular cancer drugs. This will drive the testicular cancer drugs market to grow at a CAGR of over 4% during the forecast period. Researchers are studying chemotherapy drugs such as cabazitaxel and gemcitabine to treat testicular cancer. They are also studying an antibody-drug conjugate, brentuximab vedotin, that combines an anti-CD30 antibody with the drug monomethyl auristatin E.
Top testicular cancer drugs companies covered in this market research report
The testicular cancer drugs market is fairly concentrated. Market vendors are focusing on developing advanced diagnostic methods for testicular cancer. By offering a complete analysis of the market’s competitive landscape and information on the products offered by the companies, this testicular cancer drugs industry analysis report will allow the clients to identify new growth opportunities and design innovative strategies to improve their share in the market.
The report offers a complete analysis of various companies including:
- Baxter
- Bristol-Myers Squibb
- Eli Lilly
- Pfizer
- Teva Pharmaceutical
Testicular cancer drugs market segmentation based on geographic regions
- Asia
- Europe
- North America
- ROW
North America will contribute to the highest growth of the global testicular cancer drugs market throughout the forecast period. The growing awareness of testicular cancer through initiatives implemented by various organizations such as the Testicular Cancer Society and Testicular Cancer Foundation is one of the major reasons for high growth of the testicular cancer drugs market in this region.
Testicular cancer drugs market segmentation based on the type
- Non-seminoma
- Seminoma
Non-seminoma is a commonly occurring type of testicular cancer and the availability of effective drugs to treat patients with non-seminoma is also high. As a result, the non-seminoma segment will account for the highest market share in the testicular cancer drugs market.
Key highlights of the global testicular cancer drugs market for the forecast years 2019-2023:
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the testicular cancer drugs market during the next five years
- Precise estimation of the global testicular cancer drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the testicular cancer drugs industry across various geographies such as Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details on factors that will challenge the growth of multivariable transmitters companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch